Active Ingredient History
Clazakizumab, an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 2)
Cachexia (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
COVID-19 (Phase 2/Phase 3)
Crohn Disease (Phase 2)
Fatigue (Phase 2)
Graft Rejection (Phase 3)
Graft vs Host Disease (Phase 2)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 2)
Organ Transplantation (Phase 2)
Stomatitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue